Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5

and 5 mg Doses Compared to Placebo

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today positive top-line results from its 168 patient Phase 2a clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache. Migraine is a debilitating, yet common neurological disorder characterized by attacks of severe headache and autonomic nervous system dysfunction. Two doses of AZ-104, 2.5 and 5 mg, met the primary endpoint of 2-hour pain-relief compared to placebo. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-104 a viable product to treat acute migraines. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 and AZ-104 are being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

"Loxapine is a potent antagonist at dopamine D2 receptors as well as serotonergic 5-HT2A receptors. While drugs that antagonize the D2 receptor are efficacious in treating migraine, it was proposed that the 5HT2A receptor antagonism might yield an improved adverse effect profile over drugs blocking primarily the D2 receptor. This dual mechanism of pharmacological action provided the scientific rationale to study AZ-104 in this proof-of-concept clinical trial," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Most people think of donating food around ... overlooked for a variety of reasons—thus making these months ... this need, Dr. Bryne Willey of AlignLife of ... center, wanted to heighten awareness of the need in ... Thanksgiving in July food drive to collect non-perishable foods ...
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 21, 2014 ... that features in-depth information and reviews of some of ... and many others, is pleased to announce that it ... of the systems. For seniors who are on a ... of medical device, this announcement comes as very welcome ...
(Date:8/20/2014)... 2014 iFitDress.com, the well-known wedding dress ... cheap evening gowns . All items in ... are priced under $100. , iFitDress.com is among ... keeps trying its best to help clients worldwide to ... members are kind and professional. According to its development ...
(Date:8/20/2014)... City, UT (PRWEB) August 20, 2014 ... Benefits Solution, announced the publication of a new ... Zane Benefits, many small business owners feel uncertain ... employees, their family, and their bottom line. , ... comprehensive FAQs, and helps businesses navigate their upcoming ...
(Date:8/20/2014)... By Dennis Thompson ... -- U.S. teen birth rates fell dramatically during the past ... dollars, a new government report shows. An estimated 4 ... the decline, according to researchers from the U.S. Centers for ... "leapt out at me from the report," said Bill Albert, ...
Breaking Medicine News(10 mins):Health News:AlignLife Springfield Office Donates 565 Canned Goods to Springfield Food Pantry 2Health News:Medical Alert Systems Website Now Offering Special Prices on the Popular Medical Guardian Product 2Health News:Medical Alert Systems Website Now Offering Special Prices on the Popular Medical Guardian Product 3Health News:iFitDress.com Releases a New Range of Cheap Evening Gowns 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3
... ages, even small changes affect incidence, study finds ... affect older adults, risk of diabetes, a new study ... lifestyle and incidence of diabetes over 10 years in ... lifestyle factors examined included physical activity, dietary habits, tobacco ...
... for first time in the Middle East and the Asia-Pacific ... of confirmed cases of swine flu in the United States ... all the new cases coming from a New York City ... infectious disease. , Some news reports Tuesday were listing the ...
... Early and Accurate Carbon Monoxide Exposure Detection Following ... Purchase Rad-57sIRVINE, Calif., April 28 ... of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion ... Pulse CO-Oximeter has been added to the Federal ...
... Challenge Faced by Troops Coming Home from WarCAMBRIDGE, Mass., ... Construction and Veterans Affairs Appropriations Subcommittee on behalf of ... Development Institute (ALS TDI), last Thursday. Dr. Appel ... therapeutic development, such as the one at ALS TDI. ...
... Solutions conducting further research to identify which processes ... While sustained excellence in cardiac care is rare, ... of cardiac care -- acute myocardial infarction (AMI), ... graft surgery (CABG) -- have more cardiac patient ...
... 28 , WHO: Myles Druckman, MD, a leading disease outbreak ... past, Dr. Druckman has been interviewed by, ... The Washington Post, about SARS, avian flu, and other, ... to discuss the swine flu outbreak and associated topics, ...
Cached Medicine News:Health News:Lifestyle Factors Tied to Older Adults' Diabetes Risk 2Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 2Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 3Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 4Health News:Some Reports Put Number of U.S. Swine Flu Cases at 50 5Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 2Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 3Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 4Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 5Health News:ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs 2Health News:ALS Therapy Development Institute Delivers Impassioned Testimony to Congressional Subcommittee on Veterans Affairs 3Health News:Sustaining Excellence in All Aspects of Cardiac Care Rare But Lives Could Be Saved If More Patients Were Treated at Top-Performing Hospitals 2Health News:Sustaining Excellence in All Aspects of Cardiac Care Rare But Lives Could Be Saved If More Patients Were Treated at Top-Performing Hospitals 3Health News:Available for Interviews: Pandemic, Disease Outbreak Expert to Discuss Swine Flu 2Health News:Available for Interviews: Pandemic, Disease Outbreak Expert to Discuss Swine Flu 3
Bone Curette, 170 mm...
Bone Currettes...
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: